No Data
No Data
No Data
No Data
No Data
Express News | Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
Moomoo 24/7Apr 15 16:05 ET
Cantor Fitzgerald Reiterates Overweight on Prothena Corp
Cantor Fitzgerald analyst Charles Duncan reiterates Prothena Corp (NASDAQ:PRTA) with a Overweight.
BenzingaApr 10 13:26 ET
Despite Shrinking by US$81m in the Past Week, Prothena (NASDAQ:PRTA) Shareholders Are Still up 108% Over 5 Years
Some Prothena Corporation plc (NASDAQ:PRTA) shareholders are probably rather concerned to see the share price fall 43% over the last three months. But that doesn't change the fact that the returns
Simply Wall StApr 5 07:25 ET
Labcorp Expands Alzheimer's Testing Portfolio With New Diagnostic
Seeking AlphaMar 20 09:00 ET
Demystifying Prothena Corp: Insights From 8 Analyst Reviews
Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Prothena Corp (NASDAQ:PRTA) in the last three months.Summarizing their recent assessments, the t
BenzingaMar 13 10:00 ET
Prothena Is Maintained at Buy by HC Wainwright & Co.
Prothena Is Maintained at Buy by HC Wainwright & Co.
Dow JonesMar 13 09:36 ET
No Data
No Data